Folinic Acid — Drug Intelligence | 89 EU Trials

Filter these 89 trials by condition, phase, country and more.

Open in Search →

89 Registered trials

35 Recruiting

41 Completed trials

56 Sponsors

23 Countries

Phase III

Phase II

Phase I/II

Phase III: 35 Phase II/III: 3 Phase II: 38 Phase I/II: 9 Phase IV: 1 Phase I (FiH): 3

Oversight events:

5 serious breaches 14 temporary halts 2 urgent safety measures 2 unexpected events 1 corrective measure across 10 trials

View oversight register →

Indications tested

Colorectal cancer 7 Colorectal cancer metastatic 5 Gastric cancer 4 Colorectal cancer stage III 3 Colorectal adenocarcinoma 3 Gastroenteropancreatic neuroendocrine tumour disease 2 Rectal cancer 2 Rectal adenocarcinoma 2 Colorectal cancer stage II 2 Adenocarcinoma of colon 2 Pancreatic carcinoma metastatic 1 Rectal cancer recurrent 1

Sponsors using this IMP

Unicancer 9 Fondation Franc.Cancerologie Digestive 8 AstraZeneca AB 4 Catharina Ziekenhuis Stichting 4 Centre Hospitalier Universitaire De Dijon 4 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 4 AbbVie Deutschland GmbH & Co. KG 3 Amgen Inc. 2 Astellas Pharma Global Development Inc. 2 Fondazione Gimema Franco Mandelli Onlus 2 Glaxosmithkline Research & Development Limited 2 1globe Health Institute LLC 1

All trials

89 total

Safety, tolerability, and efficacy of mFOLFIRINOX ±BNT321 as adjuvant therapy following curative resection in patients with pancreatic adeno… Not authorised

2023-506014-47-00 Phase I/II 4 countries BioNTech SE
Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with… Pending

2024-512318-16-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancer. Pending

2024-518570-13-00 Phase II/III 2 countries Catharina Ziekenhuis Stichting
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending

2024-519753-11-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cance… Pending

2024-519787-40-00 Phase III 8 countries AstraZeneca AB
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test Pending

2025-521045-24-00 Phase III 2 countries Unicancer
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending

2025-521209-42-00 Phase IV 3 countries Fondazione GONO G.I.
Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending

2025-521619-37-00 Phase III 1 country Unicancer
Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col… Pending

2025-522377-12-00 Phase III 1 country Charite Universitaetsmedizin Berlin KöR
Liver-directed chemotherapy after surgery of liver metastases of colorectal cancer in patients with high risk of recurrence of their disease… Pending

2025-523913-27-00 Phase III 1 country Unicancer
A Phase 1b-2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and … Pending

2026-525629-20-00 Phase I/II 1 country Larkspur Biosciences Inc.
RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting

2024-514327-42-00 Phase II 2 countries Grupo Espanol De Tumores Neuroendocrinos
BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours Recruiting

2024-517500-11-00 Phase I (FiH) 4 countries Bold Therapeutics Inc.
Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tum… Recruiting

2024-518131-11-02 Phase II 1 country Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospita…
Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed b… Recruiting

2024-518143-38-00 Phase II/III 1 country Fondation Franc.Cancerologie Digestive
Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study Recruiting

2024-510617-15-00 Phase III 2 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The… Recruiting

2022-500966-82-00 Phase III 4 countries Karolinska University Hospital
A Study of S241656 in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Recruiting

2025-523474-16-00 Phase I (FiH) 4 countries Institut De Recherches Internationales Servier IRIS
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Recruiting

2025-521587-35-00 Phase III 8 countries Summit Therapeutics Inc.
Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer Recruiting

2025-520471-29-00 Phase III 1 country Fundacion Para La Investigacion Biomedica De Cordoba
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait A… Recruiting

2025-523692-39-00 Phase III 1 country Catharina Ziekenhuis Stichting
PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
A Phase 1b/2 study of GSK5764227 in combination with Standard of Care (SoC) or other agents in participants with advanced solid tumors Recruiting

2025-522274-37-00 Phase I/II 1 country Glaxosmithkline Research & Development Limited

Showing 1–24 of 89 trials

← All drugs A–Z